ArticleFrontiers in neuroscience2010
Central tetrahydrobiopterin concentration in neurodevelopmental disorders.
Article in Frontiers in neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01141595 (Biomarkers of Central Nervous System Tetrahydrobiopterin Concentration and Response to Tetrahydrobiopterin Supplementation in Children With Idiopathic Cognitive Developmental Disorders), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarkers of Central Nervous System Tetrahydrobiopterin Concentration and Response to Tetrahydrobiopterin Supplementation in Children With Idiopathic Cognitive Developmental Disorders
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor.Molecular neurobiology · 2026Article
- Cerebral folate deficiency, developmental difficulties in autism spectrum disorder and the role of leucovorin: a narrative review of mechanisms and clinical evidence.Drugs in context · 2026Review
- Transgenerational Effects and Heritability of Folate Receptor Alpha Autoantibodies in Autism Spectrum Disorder.International journal of molecular sciences · 2025Article
- Tetrahydrobiopterin and Autism Spectrum Disorder: A Systematic Review of a Promising Therapeutic Pathway.Brain sciences · 2025Review
- Central Causation of Autism/ASDs via Excessive [CaBrain sciences · 2024Review
- Tetrahydrobiopterin in Cell Function and Death Mechanisms.Antioxidants & redox signaling · 2022Review
- Tetrahydrobiopterin and Its Multiple Roles in Neuropsychological Disorders.Neurochemical research · 2022Review
- Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin (Folinic Acid) Treatment in Autism Spectrum Disorders: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2021Review
- Paving Plant-Food-Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder.Oxidative medicine and cellular longevity · 2021Article
- Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder.Seminars in pediatric neurology · 2020Review
- Article
- Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents.CNS drugs · 2018Review
- Comparison of Treatment for Metabolic Disorders Associated with Autism:Reanalysis of Three Clinical Trials.Frontiers in neuroscience · 2018Article
- Modulation of mitochondrial function by the microbiome metabolite propionic acid in autism and control cell lines.Translational psychiatry · 2016Article
- Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes.Clinical medicine insights. Pediatrics · 2016Review
- Treatments for biomedical abnormalities associated with autism spectrum disorder.Frontiers in pediatrics · 2014Review
- Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study.Translational psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Tetrahydrobiopterin (BH(4)) is a naturally occurring cofactor essential for critical metabolic pathways. Studies suggest that BH(4) supplementation may ameliorate autism symptoms; the biological mechanism for such an effect is unknown. To help understand the relation between central BH(4) concentration and systemic metabolism and to develop a biomarker of central BH(4) concentration, the relationship between cerebrospinal fluid BH(4) concentration and serum amino acids was studied. BH(4) concentration was found to be distributed in two groups, a lower and higher BH(4) concentration group. Two serum amino acids, citrulline and methionine, differentiated these groups, and the ratio of serum citrulline-to-methionine was found to correlate with the cerebrospinal fluid BH(4) concentration (r = -0.67, p < 0.05). Both citrulline and methionine are substrates in inflammation and oxidative stress pathways - two pathways that utilize BH(4) and are abnormally activated in autism. These data suggests that central BH(4) concentration may be related to systemic inflammation and oxidative stress pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.